Aktis Oncology, Inc.

NASDAQ:AKTS

Biotechnology

Healthcare
$16.10 +0.47%

+$0.11 today

Market cap
$865.32M
Beta
1.10
P/E (TTM)
-28.7
EPS (TTM)
-$0.82
52W Low $14.72High $29.16

Volume 0.44M

Average 0.33M

Balance Sheet

Inspect the capital base behind the business.

Assets

$264.88M

FY 2025 · Annual

-18.8% YoY

Liabilities

$411.03M

FY 2025 · Annual

-0.7% YoY

Equity

-$146.15M

FY 2025 · Annual

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents128.6M29.51M37.16M37.78M
Short-term Investments068.35M260.01M189M
Net Receivables0000
Inventory0000
Other Current Assets3.88M2.34M3.69M3.52M
Total Current Assets132.48M100.2M300.85M230.31M
Property, Plant & Equipment (Net)4.87M20.92M20.87M27.25M
Goodwill0000
Intangible Assets0000
Long-term Investments0000
Tax Assets0000
Other Non-current Assets976K1.23M4.46M7.33M
Total Non-current Assets5.84M22.15M25.33M34.58M
Total Assets138.32M122.36M326.18M264.89M
Account Payables490K957K1.92M1.74M
Short-term Debt0000
Tax Payables0000
Deferred Revenue009.28M18.66M
Other Current Liabilities1.19M2.03M3.08M4.56M
Total Current Liabilities5.28M6.24M18.82M31.24M
Long-term Debt0000
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0051.04M36.16M
Other Non-current Liabilities151.36M150.55M333.41M333.41M
Total Non-current Liabilities152.28M162.42M395.16M379.8M
Total Liabilities157.55M168.66M413.98M411.03M
Common Stock0000
Retained Earnings(20.21M)(48.85M)(92.83M)(156.56M)
Accumulated OCI082K124K42K
Other Stockholders Equity0000
Minority Interest0000
Total Equity(19.23M)(46.31M)(87.8M)(146.15M)
Total Debt1.78M13.4M12.01M11.55M
Net Debt(126.82M)(16.11M)(25.15M)(26.24M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$371.6M
Short-term Investments$166.9M
Receivables$2.2M
Other Current$3.3M
Total Current Assets$543.9M
PP&E (Net)$28.1M
Long-term Investments$1.1M
Other Non-current$3.6M
Total Non-current Assets$32.9M
Total Assets$576.8M

Analysis

Selected assets total $576.8M for Latest. The largest visible component is Cash & Equivalents at $371.6M, about 64.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
4Statement of changes in beneficial ownershipSep 24, 2026
10-QQuarterly reportAug 13, 2026
8-KCurrent reportAug 13, 2026

How much cash does AKTS have?

Aktis Oncology, Inc. (AKTS) reported $37.78M in cash and equivalents in fiscal 2025.

How much debt does AKTS carry?

Aktis Oncology, Inc. (AKTS) reported $11.55M of total debt, with net debt of -$26.24M.